George C,Deroide F,Rustin M. .2019 .Pyoderma gangrenosum - a guide to diagnosis and management. Clin Med, 19(3) : 224-8.
Wollina U. Pyoderma .2007 .. Orphanet J Rare Dis, 2 : 19.
Butcher M. .2005 .Pyoderma gangrenosum: a diagnosis not to be missed. WOUNDS UK, 1(3) : 84.
Fulbright RK,Wolf JE,Tschen JA .1985 .Residents' corner: pyoderma gangrenosum at surgery sites. J Dermatol Surg Oncol, 11(9) : 883-6.
Adachi Y,Kindzelskii AL,Cookingham G,Shaya S,Moore EC,Todd RF .1998 .Aberrant neutrophil trafficking and metabolic oscillations in severe pyoderma gangrenosum. J Invest Dermatol, 111(2) : 259-68.
van den Berg TK,Kuijpers TW .2013 .Leukocyte adhesion deficiencies. Hematol Oncol Clin North Am, 27(1) : 101-16.
Su WP,Davis MD,Weenig RH,Powell FC,Perry HO .2004 .Pyoderma gangrenosum: clinicopathologic correlation and proposed diagnostic criteria. Int J Dermatol, 43(11) : 790-800.
Menter A,Gottlieb A,Feldman SR,Van Voorhees AS,Leonardi CL,Gordon KB .2008 .Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol, 58(5) : 826-50.
Sandborn WJ,Targan SR .2002 .Biologic therapy of inflammatory bowel disease. Gastroenterology, 122(6) : 1592-1608.
Chow RK,Ho VC .1996 .Treatment of pyoderma gangrenosum. J Am Acad Dermatol, 34(6) : 1047-60.
Wang AS,Armstrong EJ,Armstrong AW .2013 .Corticosteroids and wound healing: clinical considerations in the perioperative period. Am J Surg, 206(3) : 410-7.
Hughes AP,Jackson JM,Callen JP. .2000 .Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA, 284(12) : 1546-8.
Goldstein F,Krain R,Thornton JJ .1985 .Intralesional steroid therapy of pyoderma gangrenosum. J Clin Gastroenterol, 7(6) : 499-501.
Jennings J .1983 .Pyoderma gangrenosum: successful treatment with intralesional steroids. J Am Acad Dermatol, 9(4) : 575-80.
Homey B,Assmann T,Vohr HW,Ulrich P,Lauerma AI,Ruzicka T .1998 .Topical FK506 suppresses cytokine and costimulatory molecule expression in epidermal and local draining lymph node cells during primary skin immune responses. J Immunol, 160(11) : 5331-40.
Schuppe HC,Homey B,Assmann T,Martens R,Ruzicka T. .1998 .Topical tacrolimus for pyoderma gangrenosum. Lancet, 351(9105) : 832.
Reich K,Vente C .1998 .Topical tacrolimus for pyoderma gangrenosum. Br J Dermatol, 139(4) : 755-7.
Sehgal VN,Srivastava G,Dogra S. .2008 .Tacrolimus in dermatology-pharmacokinetics, mechanism of action, drug interactions. dosages, and side effects: part I. Skinmed, 7(1) : 27-30.
Tamir A,Landau M,Brenner S. .1996 .Topical treatment with 1% sodium cromoglycate in pyoderma gangrenosum. Dermatology, 192(3) : 252-4.
Saffouri B,Hom BM,Mertesdorf JM,Gardiner JF JM .1984 .Treatment of pyoderma gangrenosum with disodium cromoglycate. Dig Dis Sci, 29 : 183-5.
De Cock K,Thorne M. .1980 .The treatment of pyoderma gangrenosum with sodium cromoglycate. Br J Dermatol, 102(2) : 231-3.
Sanders C,Hulsmans R. .1993 .Successful treatment of pyoderma gangrenosum with topical 5-aminosalicylic acid. Cutis, 51(4) : 262-4.
Ahronowitz I,Harp J,Shinkai K. .2012 .Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol, 13 : 191-211.
Tsele E,Yu R,Chu A .1992 .Pyoderma gangrenosum-response to topical nitrogen mustard. Clin Exp Dermatol, 17(6) : 437-40.
Nguyen L,Weiner J .1977 .Treatment of pyoderma gangrenosum with benzoyl peroxide. Cutis, 19(6) : 842-4.
Vereecken P,Wautrecht JC,De Dobbeleer G,Heenen M. .1997 .A case of pyoderma gangrenosum stabilized with lymecycline, topical benzoyl peroxide and treated by autograft. Dermatology, 195(1) : 50-1.
.2004 .Nicotine effects on skin: are they positive or negative?. Exp Dermatol, 13(11) : 665-70.
Wolf R,Ruocco V .1998 .Nicotine for pyoderma gangrenosum. Arch Dermatol, 134(9) : 1071-2.
Heldin CH,Westermark B. Mechanism .1999 .of action and in vivo role of platelet-derived growth factor. Physiol Rev, 79(4) : 1283-316.
Braun-Falco M,Kovnerystyy O,Lohse P,Ruzicka T. .2012 .Pyoderma gangrenosum, acne, and suppurative hidradenitis (PASH)-a new autoinflammatory syndrome distinct from PAPA syndrome. J Am Acad Dermatol, 66(3) : 409-15.
Morrissey PJ,Grabstein KH,Reed SG,Conlon PJ .1989 .Granulocyte/macrophage colony stimulating factor. A potent activation signal for mature macrophages and monocytes. Int Arch Allergy Immunol, 88(1-2) : 40-5.
White LE,Villa MT,Petronic-Rosic V,Jiang J,Medenica MM .2006 .Pyoderma gangrenosum related to a new granulocyte colony-stimulating factor. Skinmed, 5(2) : 96-8.
Callen JP .1998 .Pyoderma gangrenosum. Lancet, 351(9102) : 581-5.
Lebbe C,Moulonguet-Michau I,Perrin P,Blanc F,Frja J,Civatte J .1992 .Steroid-responsive pyoderma gangrenosum with vulvar and pulmonary involvement. J Am Acad Dermatol, 27(4) : 623-5.
Gupta AK,Brown MD,Ellis CN,Rocher LL,Fisher GJ,Baadsgaard O .1989 .Cyclosporine in dermatology. J Am Acad Dermatol, 21(6) : 1245-56.
Matis WL,Ellis CN,Griffiths CE,Lazarus GS .1992 .Treatment of pyoderma gangrenosum with cyclosporine. Arch Dermatol, 128(8) : 1060-4.
Gasior-Chrzan B,Stenvold S,Falk E .1995 .Treatment of pyoderma gangrenosum with cyclosporine. J Eur Acad Dermatol Venereol, 5 : S162.
Ahmed AR,Hombal SM .1984 .Cyclophosphamide (Cytoxan): a review on relevant pharmacology and clinical uses. J Am Acad Dermatol, 11(6) : 1115-26.
Newell LM,Malkinson FD .1983 .Pyoderma gangrenosum: response to cyclophosphamide therapy. Arch Dermatol, 119(6) : 495-7.
Crawford SE,Sherman R,Favara B .1967 .Pyoderma gangrenosum with response to cyclophosphamide therapy. J Pediatr, 71(2) : 255-8.
Cronstein BN .1996 .Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum, 39(12) : 1951-60.
Teitel .1996 .A. Treatment of pyoderma gangrenosum with methotrexate. Cutis, 57(5) : 326-8.
Brown R,Lay L,Graham D. .1993 .Bilateral pyoderma gangrenosum of the hand: treatment with dapsone. J Hand Surg, 18(1) : 119-21.
Perri III AJ,Hsu S. .2003 .A review of thalidomide's history and current dermatological applications. Dermatol Online J, 9(3) : 5.
Federman GL,Federman DG .2000 .Recalcitrant pyoderma gangrenosum treated with thalidomide. Mayo Clin Proc, 75(8) : 842-4.
Thomsen K,Rothenborg HW .1979 .Clofazimine in the treatment of pyoderma gangrenosum. Arch Dermatol, 115(7) : 851-2.
Michaëlsson G,Molin L,Ohmann S,Gip L,Lindström B,Skogh M .1976 .Clofazimine: a new agent for the treatment of pyoderma gangrenosum. Arch Dermatol, 112(3) : 344-9.
Abu-Elmagd K,Van Thiel DH,Jegasothy BV,Jacobs JC,Carroll P,Rodriquez-Rilo H .1993 .Resolution of severe pyoderma gangrenosum in a patient with streaking leukocyte factor disease after treatment with tacrolimus (FK 506). Ann Intern Med, 119(7) : 595-8.
Weichert G,Sauder DN .1998 .Efficacy of tacrolimus (FK 506) in idiopathic treatment-resistant pyoderma gangrenosum. J Am Acad Dermatol, 39(4) : 648-50.
Bhat RM .2004 .Management of pyoderma gangrenosum-An update. Indian J Dermatol Venereol Leprol, 70(6) : 329-35.
Breathnach S,Wells G,Valdimarsson H .1981 .Idiopathic pyoderma gangrenosum and impaired lymphocyte function: failure of azathioprine and corticosteroid therapy. Br J Dermatol, 104(5) : 567.
Davies M,Piper S M .1981 .Pyoderma gangrenosum: successful treatment with minocycline. Clin Exp Dermatol, 6(2) : 219-23.
Burruss JB,Farmer ER,Callen JP .1996 .Chlorambucil is an effective corticosteroid-sparing agent for recalcitrant pyoderma gangrenosum. J Am Acad Dermatol, 35(5) : 720-4.
Gelernt I,Kreel I. .1976 .Pyoderma gangrenosum in ulcerative colitis: prevention of the gangrenous component. Mt Sinai J Med, 43(4) : 467-70.
Cliff S,Holden CA,Thomas PR,Marsden RA,Harland CC .1999 .Split skin grafts in the treatment of pyoderma gangrenosum: a report of four cases. Dermatol Surg, 25(4) : 299-302.
Fonder MA,Lazarus GS,Cowan DA,Aronson-Cook B,Kohli AR,Mamelak AJ .2008 .Treating the chronic wound: A practical approach to the care of nonhealing wounds and wound care dressings. J Am Acad Dermatol, 58(2) : 185-206.
Gottrup F,Karlsmark T. .2005 .Leg ulcers: uncommon presentations. Clin Dermatol, 23(6) : 601-11.
Le Cleach L,Moguelet P,Perrin P,Chosidow O .2011 .Is topical monotherapy effective for localized pyoderma gangrenosum?. Arch Dermatol, 147(1) : 101-3.
Fonseka HF,Ekanayake SM,Dissanayake M. .2010 .Two percent topical phenytoin sodium solution in treating pyoderma gangrenosum: a cohort study. Int Wound J, 7(6) : 519-23.
Bellini V,Simonetti S,Lisi P. .2008 .Successful treatment of severe pyoderma gangrenosum with pimecrolimus cream 1%. J Eur Acad Dermatol Venereol, 22(1) : 113-5.
Piccirillo A,Ricciuti F .2006 .Topical tacrolimus for pyoderma gangrenosum: another report. J Dermatol, 33(3) : 232.
Chiba T,Kiehl P,Breuer C,Kapp A,Werfel T. .2005 .Topical tacrolimus therapy for pyoderma gangrenosum. J Dermatol, 32(3) : 199-203.
Fraccalvieri M,Fierro MT,Salomone M,Fava P,Zingarelli EM,Cavaliere G .2014 .Gauze‐based negative pressure wound therapy: a valid method to manage pyoderma gangrenosum. Int Wound J, 11(2) : 164-8.
Chriba M,Skellett A,Levell N. .2010 .Beclometasone inhaler used to treat pyoderma gangrenosum. Clin Exp Dermatol, 35(3) : 337-8.
Kluger N. .2012 .Can snus (Swedish moist snuff) be used as a treatment of Pyoderma gangrenosum?. Med Hypotheses, 78(5) : 619-20.
Rutgeerts P,Vermeire S .2009 .Biological therapies for inflammatory bowel diseases. Gastroenterology, 136(4) : 1182-97.
Reguiai Z,Grange F. .2007 .The role of anti-tumor necrosis factor-α therapy in pyoderma gangrenosum associated with inflammatory bowel disease. Am J Clin Dermatol, 8 : 67-77.
Gisondi P,Girolomoni G .2007 .Biologic therapies in psoriasis: a new therapeutic approach. Autoimmun Rev, 6(8) : 515-9.
Brooklyn TN,Dunnill MG,Shetty A,Bowden JJ,Williams JD,Griffiths CE .2006 .Infliximab for the treatment of pyoderma gangrenosum: a randomised, double blind, placebo controlled trial. Gut, 55(4) : 505-9.
Regueiro M,Valentine J,Plevy S,Fleisher MR,Lichtenstein GR .2003 .Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol, 98(8) : 1821-6.
Traczewski P,Rudnicka L .2008 .Adalimumab in dermatology. Br J Clin Pharmacol, 66(5) : 618-25.
Fonder MA,Cummins DL,Ehst BD,Anhalt GJ,Meyerle JH .2006 .Adalimumab therapy for recalcitrant pyoderma gangrenosum. J Burns Wounds, 5 : e8.
Heffernan MP,Anadkat MJ,Smith DI .2007 .Adalimumab treatment for pyoderma gangrenosum. Arch Dermatol, 143(3) : 306-8.
Goffe B,Cather JC .2003 .Etanercept: an overview. J Am Acad Dermatol, 49(2) : 105-11.
Gardam MA,Keystone EC,Menzies R,Manners S,Skamene E,Long R .2003 .Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis, 3(3) : 148-55.
Pastor N,Betlloch I,Pascual JC,Blanes M,Bañuls J,Silvestre JF .2006 .Pyoderma gangrenosum treated with anti‐TNF alpha therapy (etanercept. Clin Exp Dermatol, 31(1) : 152-3.
Goldenberg G,Jorizzo JL .2005 .Use of etanercept in treatment of pyoderma gangrenosum in a patient with autoimmune hepatitis. J Dermatol Treat, 16(5-6) : 347-9.
Charles CA,Leon A,Banta MR,Kirsner RS .2007 .Etanercept for the treatment of refractory pyoderma gangrenosum: a brief series. Int J Dermatol, 46(10) : 1095-9.
Ruocco E,Sangiuliano S,Gravina AG,Miranda A,Nicoletti G .2009 .Pyoderma gangrenosum: an updated review. J Eur Acad Dermatol Venereol, 23(9) : 1008-17.
Graves JE,Nunley K,Heffernan MP .2007 .Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). J Am Acad Dermatol, 56(1) : e55-79.
Foss CE,Clark AR,Inabinet R,Camacho F,Jorizzo JL .2008 .An open‐label pilot study of alefacept for the treatment of pyoderma gangrenosum. J Eur Acad Dermatol Venereol, 22(8) : 943-9.
Miller J,Yentzer BA,Clark A,Jorizzo JL,Feldman SR .2010 .Pyoderma gangrenosum: a review and update on new therapies. J Am Acad Dermatol, 62(4) : 646-54.
Wollina U .2011 .Pyoderma gangraenosum. Curr Opin Rheumatol, 23(1) : 50-6.
Lorincz M,Kleszky M,Szalóki T .2010 .Pyoderma gangrenosum treated successfully with visilizumab in patients with ulcerative colitis. Orv Hetil, 151(4) : 144-7.
Guenova E,Teske A,Fehrenbacher B,Hoerber S,Adamczyk A,Schaller M .2011 .Interleukin 23 expression in pyoderma gangrenosum and targeted therapy with ustekinumab. Arch Dermatol, 147(10) : 1203-5.
Allison AC,Eugui EM .2000 .Mycophenolate mofetil and its mechanisms of action. Immunopharmacology, 47(2- 3) : 85-118.
Eaton PA,Callen JP .2009 .Mycophenolate mofetil as therapy for pyoderma gangrenosum. Arch Dermatol, 145(7) : 781-5.
Cummins DL,Anhalt GJ,Monahan T,Meyerle JH .2007 .Treatment of pyoderma gangrenosum with intravenous immunoglobulin. Br J Dermatol, 157(6) : 1235-9.
Qiu L,Zheng S,Wu J,Xiao T,Chen HD .2012 .Refractory disseminated pyoderma gangrenosum, with dependence on corticosteroids, responding to potassium iodide. Eur J Dermatol, 22(3) : 426-7.
Saniabadi AR,Hanai H,Takeuchi K,Umemura K,Nakashima M,Adachi T .2003 .Adacolumn, an Adsorptive Carrier Based Granulocyte and Monocyte Apheresis Device for the Treatment of Inflammatory and RefractoryDiseases Associated with Leukocytes. Ther Apher Dial, 7(1) : 48-59.
Okuma K,Mitsuishi K,Hasegawa T,Tsuchihashi H,Ogawa H,Ikeda S H .2007 .A case report of steroid and immunosuppressantresistant pyoderma gangrenosum successfully treated by granulocytapheresis. Ther Apher Dial, 11(5) : 387-90.
de Imus G,Golomb C,Wilkel C,Tsoukas M,Nowak M,Falanga V .2001 .Accelerated healing of pyoderma gangrenosum treated with bioengineered skin and concomitant immunosuppression. J Am Acad Dermatol, 44(1) : 61-6.
Duchini G,Itin P,Arnold A. .2011 .A case of refractory pyoderma gangrenosum treated with a combination of Apligraf and systemic immunosuppressive agents. Adv Skin Wound Care, 24(5) : 217-20.
Altunay I,Kucukunal A,Sarikaya S .2014 .A favourable response to surgical intervention and hyperbaric oxygen therapy in pyoderma gangrenosum. Int Wound J, 11(4) : 350-3.
Li LF .2000 .Treatment of pyoderma gangrenosum with oral Tripterygium wilfordii multiglycoside. J Dermatol, 27(7) : 478-81.